6-K 1 ef20017972_6k.htm 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2024
Commission File Number: 001-38283

InflaRx N.V.
(Translation of registrant's name into English)

Winzerlaer Str. 2
07745 Jena, Germany
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE
On January 4, 2024, InflaRx N.V. (the “Company”) issued a press release titled “InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
In connection with such announcement, also on January 4, 2024, the Company hosted a conference call and presented its corporate presentation. A copy of the corporate presentation is attached hereto as Exhibit 99.2 and is incorporated by reference herein.
2

EXHIBIT INDEX

Exhibit No. | Description
99.1 | Press Release, dated January 4, 2024
99.2 | Corporate Presentation, dated January 4, 2024

3

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| INFLARX N.V.
Date: January 4, 2024 | By: | /s/ Niels Riedemann
| Name: | Niels Riedemann
| Title: | Chief Executive Officer

4